Introduction {#s1}
============

*Tripterygium wilfordii* Hook F (TwHF), a vine plant, is used as a Chinese herbal medicine (CHM). Currently, the root of TwHF is the main officinal part used in medicinal applications, although its stem and leaf also have the same chemical composition and function as those of the root. TwHF has anti-inflammatory, anti-fertility, anti-tumor, antibacterial, ([@B37]) and other biological activities. It has determinate and curative effects on immune disorders and is an efficient substitute drug for autoimmune diseases ([@B26]). Owing to the adverse effects (AEs) of TwHF in clinical preparations, methods for reducing the toxicity and increasing the efficacy of TwHF are being extensively investigated. In order to unify TwHF preparations in the statistics, we analyzed studies that included only the use of *T. wilfordii* tgpolyglycoside (TWP) treatment. TWP is the most widely used TwHF preparation in clinical application for kidney disease, rheumatism, Crohn's disease, skin diseases, thyroid problems, and Sjogren's syndrome ([@B30]). Several active ingredients such as triptolide, triptonide, celastrol, wilforlide A, and wilforine are contained in TWP, which extracted from TwHF with elimination of the main toxic components ([@B44]). Despite the sophistication of the drug purification process, related AEs still occur intermittently.

Different types of complex and challenging AEs have evolved owing to the wide clinical application of TwHF. Previous studies have shown that the AEs caused by TWP mainly include leukopenia, gastrointestinal reactions, menstrual disorders, and liver dysfunction ([@B56]). Incidences of leukopenia and liver dysfunction have significantly increased in patients treated for immune system disease, and independent incidences of AEs caused by TwHF have been associated with various organ toxicities, such as intestinal toxicity, reproductive toxicity, hepatotoxicity, nephrotoxicity, hematotoxicity, and cutaneous toxicity ([@B28]; [@B57]). This indicates that the therapeutic dose of TwHF is close to its toxic dose, resulting in unavoidable occurrence of AEs. However, its safety can be controlled within acceptable limits ([@B45]; [@B65]). Hence, the China State Food and Drug Administration issued a drug warning on TwHF preparations in April 2012 to restrict its clinical application ([@B43]).

Although some patients experience AEs due to TwHF, reasonable treatment and management strategies can help improve their tolerance to the plant. The dosage and treatment courses of TwHF should be strictly controlled, and patients treated with TwHF should be closely observed for AEs. TwHF-induced AEs attracted public attention for the first time in 2013 ([@B4]). However, researchers have focused on the incidence of AEs in a single systemic disease (primary nephrotic syndrome), although TwHF is a multi-systemic drug used for treating multi-systemic diseases. Therefore, high-quality meta-analyses of the AEs associated with TwHF are needed.

TWP, the most common preparation of TwHF in clinical practice, was the object of analysis of this study. We collected and analyzed articles on AEs caused by TWP and investigated the main AEs and risk factors associated with TwHF to provide references for future clinical safety.

Methods {#s2}
=======

This systematic review was performed following the Cochrane Handbook for Systematic Reviews of Interventions, ([@B10]) presented under the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines shown in [**Supplementary Table 3**](#SM1){ref-type="supplementary-material"}.

Selection Criteria {#s2_1}
------------------

In this analysis, we included studies of randomized controlled trials (RCTs), controlled clinical trials (CCTs), and single-arm trials reporting AEs after the intervention of TWP, irrespective of sex, age, and ethnicity.

The exclusion criteria were as follows: (i) studies on non-TWP extract or compound; (ii) studies not reporting AEs; (iii) articles of meeting abstracts, cell or animal studies, reviews, systematic reviews, and meta-analysis; and (iv) articles with full text not available.

Outcomes {#s2_2}
--------

The primary outcomes considered in this study were the incidence of AEs and their grades, which were recorded according to the Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0) of the National Cancer Institute. AE grades ≥3 were considered severe. AE incidence was evaluated in terms of drug dosage, treatment duration, combined interventions, and pharmaceutical manufacturers as the primary outcome. Organ-specific AEs were measured as the secondary outcomes.

Selection of Studies and Data Extraction {#s2_3}
----------------------------------------

The Cochrane Library, Excerpta Medica Database (EMBASE), PubMed, and Web of Science (WOS) were searched in this study. Studies dating from the earliest citation in the databases till November 2018 were included irrespective of language. The search terms used were "safety," "side effects," and "adverse events," combined with "*Tripterygium wilfordii* Hook F.," "*Tripterygium wilfordii* tgpolyglycoside," "Lei Gong Teng," and "clinical."

Three investigators independently screened the studies according to the inclusion criteria using self-designed data-extraction templates, and extracted information that included the first author, study characteristics (article type, year, and design), drug characteristics (medication dosage, pharmaceutical manufacturers, combined interventions, administration route, and drug duration), participant characteristics (region, sex, mean age, sample size, and diagnosis), and AE characteristics (incidence rate, occurrence time, specific AE manifestations, and solutions), and then measured the outcomes. Two authors assessed the risk of bias, three authors performed data analysis and interpretation, four authors performed statistical analyses, three authors drafted the manuscript, and all authors read and approved the final manuscript.

Quality Assessments {#s2_4}
-------------------

The Cochrane Handbook ([@B10]) was used to evaluate the methodological quality of the included RCTs regarding the following characteristics: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting, and other biases. The terms "low," "unclear," and "high" referred to low, uncertain, and high risks of bias, respectively. The quality of non-RCTs was evaluated using the Newcastle--Ottawa Scale (NOS) ([@B40]) The results were cross-checked by two investigators, and disagreements were settled *via* discussion.

Statistical Analysis {#s2_5}
--------------------

The incidence of AEs was estimated for the studies included in this meta-analysis. We pooled the incidence of AEs in TWP treatment. Heterogeneity between studies was assessed using the Q test and *I* ^2^ statistics. When the heterogeneity was small, that is when *I* ^2^ \< 50%, the fixed-effect model was used for analysis, and when the heterogeneity was large, that is when *I* ^2^ \< 50% and *P* \> 0.1, the random-effect model was used for analysis. The overall heterogeneity of the results in this meta-analysis was large; hence, the random-effect model was used to calculate the average statistics of the weighted combination of multiple research statistics. Potential publication bias was examined using funnel plots. Incidence and meta-regression analyses were performed using R software \[version 3.8.6 (2018--3--15); Nordic Cochrane Centre, Copenhagen, Denmark\] with the package Meta and Metafor function.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

Our search strategy identified 2138 potential studies from electronic databases, and the detailed steps are shown in [**Figure 1**](#f1){ref-type="fig"}. In total, 818 articles were excluded because of duplication and 1321 studies were reserved temporarily. The remaining articles were screened for titles and abstracts, and 172 studies were saved based on our inclusion and exclusion criteria. Furthermore, 126 studies were excluded as they did not meet our expectations upon perusing the entire text. Finally, we included 46 studies ([@B1]; [@B16]; [@B60]; [@B42]; [@B13]; [@B62]) in the meta-analysis.

![Flow diagram of literature search and selection. EMBASE, Excerpta Medica Database; RCT, randomized controlled trial; CCT, controlled clinical trial.](fphar-10-01250-g001){#f1}

Study Characteristics {#s3_2}
---------------------

Specific details of the clinical trials are presented in [**Table 1**](#T1){ref-type="table"} and [**Figure 2**](#f2){ref-type="fig"}. Overall, 2437 enrolled TWP-treated participants were included in the meta-analysis. There were 25 RCTs, 13 CCTs, and 8 single-arm trials. Seven of these were retrospective studies and 39 were prospective studies ([**Figure 3**](#f3){ref-type="fig"}). Among the 46 studies, at least one study used TWP as a treatment approach, which was defined as an experimental group or a control group. The sample size of the 46 trials ranged from 1 to 210. Twenty-one studies (with 1075 patients) used TWP as the primary and only treatment approach. Twenty-nine studies (with 1441 patients) used TWP as the active group, and 15 studies (with 658 patients) were used as the control group.

###### 

Characteristics of the included trials.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies   Article type   Age/Mean \[SD\]                                                               Region            Treatment centre                                                                                                   Sample size                                                                                                                                                                                                Diagnosis                                       Total incidence of AEs (number)   Source   Species, concentration (Triptolide; Tripterifordin; Celastrol, μg/g) ([@B31])   Quality control reported (Y/N)   Chemical analysis reported (Y/N)
  --------- -------------- ----------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------- -------- ------------------------------------------------------------------------------- -------------------------------- ----------------------------------
  [@B1]     CCT            41.83 \[1.02\]                                                                China Beijing     Department of Urology, Chinese PLA General Hospital                                                                87                                                                                                                                                                                                         Kidney transplantation                          NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC ([@B50])

  [@B16]    Single-arm     NR                                                                            China Jiangsu     NR                                                                                                                 13                                                                                                                                                                                                         Nephrotic syndrome                              92.31% ([@B40])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B60]    RCT            29.5 \[13.2\]                                                                 China Shanghai    NR                                                                                                                 30                                                                                                                                                                                                         Islet transplantation                           10% ([@B44])                      FH       9.78; 92.46; 398.45                                                             Y-WS3-98                         Y-HPLC

  [@B42]    Single-arm     35-40                                                                         China Jiangsu     Jiangsu Family Planning Research Institute                                                                         12                                                                                                                                                                                                         Psoriasis                                       NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B13]    CCT            **Group A:** 35.4 \[7.3\]; **Group B:** 34.4 \[9.4\]                          China Jiangsu     Nanjing General Hospital of Nanjing Military Region                                                                **Group A:** 19;\                                                                                                                                                                                          Kidney transplantation                          NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                                                                                                                                                                                                                                              **Group B:** 20                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B62]    CCT            **Group A:** 46.5 \[11.1\]; **Group B:** 49.8 \[11.7\]; **Group C-G:** NC;\   China Shanghai    Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Chinese and Western Medicine                  **Group A:** 20; **Group B:** 50; **Group C:** 40; **Group D:** 47; **Group E:** 36; **Group F:** 27; **Group G:** 4; **Group H:** 15; **Group I:** 26; **Group J:** 18; **Group K:** 30; **Group L:** 7   Rheumatoid arthritis                            75.71% (159)                      MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group H:** ≤40;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                           **Group I:** 41--50;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                           **Group J:** 51--60;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                           **Group K:** 61-70;\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                           **Group L:** \>70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B21]    Single-arm     **Case A:** 22;\                                                              China Beijing     The Third Hospital of Beijing Medical University                                                                   2                                                                                                                                                                                                          **Case A:** Pyoderma;\                          100% ([@B30])                     NR       NR                                                                              N                                N
                           **Case B:** 41                                                                                                                                                                                                                                                                                                                                                                                                                **Case B:** Gangrenosum                                                                                                                                                                                     

  [@B51]    RCT            58.6 \[2.6\]                                                                  China Shanghai    Department of Rheumatology, Shanghai Guanghua Hospital of Integrated Chinese and Western Medicine                  35                                                                                                                                                                                                         Rheumatoid arthritis                            22.86% ([@B45])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B12]    RCT            40.16 \[18.22\]                                                               China Shanxi      NR                                                                                                                 39                                                                                                                                                                                                         Rheumatoid arthritis                            NR                                NR       NR                                                                              N                                N

  [@B17]    RCT            9.4 \[2.2\]                                                                   China Jiangsu     Department of Pediatrics, Affiliated Hospital of Nanjing University of TCM                                         31                                                                                                                                                                                                         Purpura nephritis                               0%                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B7]     CCT            44.9                                                                          China Shanghai    Renji Hospital                                                                                                     65                                                                                                                                                                                                         Uterine leiomyoma                               35.40% ([@B7])                    MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B46]    CCT            NR                                                                            China Jiangsu     Nanjing General Hospital of Nanjing Military Region                                                                15                                                                                                                                                                                                         Graves ophthalmopathy                           6.67% ([@B37])                    NR       NR                                                                              N                                N

  [@B64]    CCT            10.7                                                                          China Hubei       Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology   51                                                                                                                                                                                                         Henoch- schonlein purpura Nephritis             NR                                HS       10.13; 102.67; 412.88                                                           Y-WS3-98                         Y-HPLC

  [@B64]    CCT            38.3 \[16.7\]                                                                 China Jiangsu     NR                                                                                                                 55                                                                                                                                                                                                         Rheumatoid arthritis                            49.09% ([@B24])                   NR       NR                                                                              N                                N

  [@B24]    RCT            43.8 \[1.65\]                                                                 China Shandong    NR                                                                                                                 47                                                                                                                                                                                                         Erosive oral lichen planus                      NR                                FH       9.78; 92.46; 398.45                                                             Y-WS3-98                         Y-HPLC

  [@B55]    RCT            41.52 \[10.48\]                                                               China Shanxi      NR                                                                                                                 40                                                                                                                                                                                                         Rheumatoid arthritis                            38.00% ([@B60])                   XL       10.11; 94.29; 381.23                                                            Y-WS3-98                         Y-HPLC

  [@B18]    RCT            35.0 \[12.1\]                                                                 China Shanghai    Department of Endocrinology, Tongji Hospital                                                                       40                                                                                                                                                                                                         Delayed autoimmune diabetes                     NR                                FH       9.78; 92.46; 398.45                                                             Y-WS3-98                         Y-HPLC

  [@B23]    RCT            52.04 \[9.30\]                                                                China Zhejiang    Zhejiang Provincal Hospital of TCM                                                                                 60                                                                                                                                                                                                         Rheumatoid arthritis                            48.10% ([@B18])                   BKKY     11.92; 98.52; 396.36                                                            Y-WS3-98                         Y-HPLC

  [@B69]    Single-arm     NR                                                                            China Jiangsu     The Affiliated Hospital of Nanjing University of TCM                                                               22                                                                                                                                                                                                         Chronic nephritis with persistent proteinuria   31.82% ([@B66])                   NR       NR                                                                              N                                N

  [@B35]    Single-arm     35.9 \[10.9\]                                                                 China Jiangsu     Multicenter Controlled Study                                                                                       20                                                                                                                                                                                                         Active Crohn's disease                          33.33% ([@B66])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B11]    RCT            **Group A:** 40.9 \[8.1\];\                                                   China Hainan      Department of Nephrology, Hainan People's Hospital                                                                 **Group A:** 15;\                                                                                                                                                                                          Kidney transplantation with proteinuria         NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 41.7 \[8.6\]                                                                                                                                                                                          **Group B:** 15                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B33]    CCT            **Group A:** 34.9 \[5.1\];\                                                   China Zhejiang    Department of Nephrology, Hangzhou Hospital of TCM                                                                 **Group A:** 24;\                                                                                                                                                                                          Chronic glomerular disease                      NR                                NT       NR                                                                              Y-WS3-98                         Y-HPLC
                           **Group B:** 36.1 \[6.0\]                                                                                                                                                                                          **Group B:** 34                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B20]    CCT            **Group A:** 13.1;\                                                           China Beijing     NR                                                                                                                 **Group A:** 9;\                                                                                                                                                                                           Children Alport syndrome                        NR                                NR       NR                                                                              N                                N
                           **Group B:** 11.6                                                                                                                                                                                                  **Group B:** 8                                                                                                                                                                                                                                                                                                                                                                                                         

  [@B14]    Single-arm     36.2 \[10.9\]                                                                 China Jiangsu     Jiangsu Province Hospital of TCM                                                                                   12                                                                                                                                                                                                         Ankylosing spondylitis                          0%                                DE       9.14; 98.96; 403.28                                                             Y-WS3-98                         Y-HPLC

  [@B58]    CCT            58.0 \[7.9\]                                                                  China Beijing     Peking Union Medical College Hospital                                                                              166                                                                                                                                                                                                        Rheumatoid arthritis                            63.25% (105)                      NR       NR                                                                              N                                N

  [@B34]    RCT            **Group A:** 40.7 \[11.9\];\                                                  China Jiangsu     Department of Nephrology, Huaihai Hospital Affiliated to Xuzhou Medical College                                    **Group A:** 9;\                                                                                                                                                                                           Steroid-resistant nephrotic syndrome            NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 42.8 \[13.5\]                                                                                                                                                                                         **Group B:** 11                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B3]     Single-arm     90                                                                            China Beijing     China-Japan Friendship Hospital                                                                                    1                                                                                                                                                                                                          Systemic lupus erythematosus                    NR                                NR       NR                                                                              N                                N

  [@B36]    RCT            18--60                                                                        China Jiangsu     Jinling Hospital, Nanjing University Medical School                                                                21                                                                                                                                                                                                         Crohn's disease                                 36.80% ([@B45])                   HS       10.13; 102.67; 412.88                                                           Y-WS3-98                         Y-HPLC

  [@B8]     RCT            51.9 \[9.8\]                                                                  China Jiangsu     Reasch Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine                            34                                                                                                                                                                                                         Diabetic nephropathy                            38.40% ([@B1])                    MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B32]    RCT            **Group A:** 51.3 \[8.3\];\                                                   China Beijing     9 general hospitals with divisions of rheumatology in China                                                        **Group A:** 69;\                                                                                                                                                                                          Rheumatoid arthritis                            47.82%\                           DE       9.14; 98.96; 403.28                                                             Y-WS3-98                         Y-HPLC
                           **Group B:** 50.6 \[8.6\]                                                                                                                                                                                          **Group B:** 69                                                                                                                                                                                                                                            ([@B52])                                                                                                                                                    

  [@B39]    RCT            37.5 \[11.2\]                                                                 China Jiangsu     6 hospitals in China                                                                                               99                                                                                                                                                                                                         Chronic primary glomerular disease              NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B59]    RCT            18--68                                                                        China Shanghai    Shanghai Dermatology Hospital                                                                                      45                                                                                                                                                                                                         Refractory chronic urticaria                    11.11% ([@B28])                   HS       10.13; 102.67; 412.88                                                           Y-WS3-98                         Y-HPLC

  [@B9]     RCT            55.12 \[8.02\]                                                                China Guangdong   Xiangmi Lake Rheumatism Branch of Shenzhen Futian District People's Hospital                                       24                                                                                                                                                                                                         Rheumatoid arthritis                            NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B53]    RCT            33.0 \[11.5\]                                                                 China Zhejiang    Department of ophthalmology, Jinhua Hospital of TCM                                                                32                                                                                                                                                                                                         Graves ophthalmopathy                           NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B29]    CCT            48.82 \[6.80\]                                                                China Zhejiang    The First Affiliated Hospital, College of Medicine, Zhejiang University                                            23                                                                                                                                                                                                         Idiopathic membranous nephropathy               26.0% ([@B57])                    DE       9.14; 98.96; 403.28                                                             Y-WS3-98                         Y-HPLC

  [@B15]    RCT            **Group A:** 46.72 \[10.71\];\                                                China Beijing     8 authorized rheumatology departments in general hospitals in China                                                **Group A:** 46;\                                                                                                                                                                                          Rheumatoid arthritis                            25.77% ([@B61])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 45.48 \[11.74\]                                                                                                                                                                                       **Group B:** 51                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B41]    RCT            **Group A:** 31 \[8\];\                                                       China Jiangsu     The Inflammatory Bowel Disease Center of Jinling Hospital                                                          **Group A:** 68;\                                                                                                                                                                                          Idiopathic refractory Nephrotic syndrome        43.17% ([@B44])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 30 \[13\]                                                                                                                                                                                             **Group B:** 71                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B68]    RCT            33.2 \[11.0\]                                                                 China Jiangsu     The Inflammatory Bowel Disease Center of Jinling Hospital                                                          45                                                                                                                                                                                                         Crohn's disease                                 48.89% ([@B17])                   MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B63]    RCT            30.5 \[3.6\]                                                                  China Zhejiang    4 hospitals in China                                                                                               69                                                                                                                                                                                                         Endometriosis                                   NR                                MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B67]    RCT            8.32 \[3.15\]                                                                 China Zhejiang    Li Huili East Hospital                                                                                             52                                                                                                                                                                                                         Purpura nephritis                               3.85% ([@B30])                    MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC

  [@B19]    Single-arm     57                                                                            China Beijing     Peking Union Medical College Hospital                                                                              1                                                                                                                                                                                                          Synovitis                                       0%                                NR       NR                                                                              N                                N

  [@B49]    CCT            **Group A:** 32.5 \[11.6\];\                                                  China Jiangsu     Yancheng Third People's Hospital                                                                                   **Group A:** 16;\                                                                                                                                                                                          IgA nephropathy                                 2.94% ([@B37])                    MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 33.6 \[11.8\]                                                                                                                                                                                         **Group B:** 18                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B38]    CCT            49.43 \[11.89\]                                                               China Beijing     Chinese PLA General Hospital                                                                                       21                                                                                                                                                                                                         Idiopathic membranous nephropathy               28.57% ([@B57])                   NR       NR                                                                              N                                N

  [@B48]    RCT            **Group A:** 58 \[3.8\];\                                                     China Tianjin     Department of Endocrinology, Tianjin First Center Hopital                                                          **Group A:** 20;\                                                                                                                                                                                          Diabetic nephropathy                            2.5% ([@B37])                     MT       9.28; 105.06; 402.88                                                            Y-WS3-98                         Y-HPLC
                           **Group B:** 59 \[4.2\]                                                                                                                                                                                            **Group B:** 20                                                                                                                                                                                                                                                                                                                                                                                                        

  [@B50]    RCT            42.0 \[12.0\]                                                                 China Beijing     Peking Union Medical College Hospital                                                                              58                                                                                                                                                                                                         Psoriasis                                       43.60% ([@B64])                   NR       NR                                                                              N                                N

  [@B65]    RCT            18--65                                                                        USA               Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital                          **Group A:** 69;\                                                                                                                                                                                          Rheumatoid arthritis                            49.28% ([@B22])                   NR       NR                                                                              N                                N
                                                                                                                                                                                                                                              **Group B:** 69                                                                                                                                                                                                                                                                                                                                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR, not reported; CCT, controlled clinical trial; RCT, randomized controlled trial; TCM, traditional Chinese medicine; AEs, adverse events; TZ, Jiangsu Taizhou Pharmaceutical Co., Ltd; HQ, Hongqi Pharmaceutical Factory of Shanghai Medical University; HS, Hubei Huangshi Feiyun Pharmaceutical Co., Ltd; XL, Hunan Xieli Pharmaceutical Co., Ltd; FH, Shanghai Fudan Fuhua Pharmaceutical Co., Ltd; BKKY, Zhejiang Prokokangyu Pharmaceutical Co., Ltd; NT, Jiangsu Nantong Pharmaceutical Co., Ltd; DE, Zhejiang, Deend Pharmaceutical Co., Ltd; MT, Jiangsu Meitong Pharmaceutical Co., Ltd; Y-WS3-98, Yes-State food and drug administration of the People's Republic of China; The 17th volume of Chinese Traditional Medicine preparations standard, No. WS3-B-3350-98; Y-HPLC, Yes-High performance liquid chromatography; TwHF, Tripterygium wilfordii Hook F.

![Pie chart for the diagnosis of diseases treated with *Tripterygium wilfordii* tgpolyglycoside.](fphar-10-01250-g002){#f2}

![Time trend of the 46 articles relevant to *Tripterygium wilfordii* tgpolyglycoside-induced adverse events (prospective studies vs. retrospective studies), search performed until November 2018. RCT, randomized controlled trial; CCT, controlled clinical trial; SA, single-arm trial.](fphar-10-01250-g003){#f3}

The overall incidence of AEs presented heterogeneity was as high as 30.75% \[95% confidence interval (CI) (21.18--40.33), *I* ^2^ = 97%\] ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). The results of meta-regression of current AEs among patients treated with TWP revealed that high-quality studies, combined medications, medication course, drug dosage, pharmaceutical manufacturers, and organ-specific AEs (*P* \< 0.05) significantly affected heterogeneity ([**Table 2**](#T2){ref-type="table"}). However, studies of lower quality were associated with higher *P* value, suggesting that studies with multivariate adjustment retained some residual confounding observations.

###### 

Potential prespecified sources of heterogeneity among the studies reporting AEs associated with TWP treatment.

  Prespecified source of heterogeneity   Number of studies   Stratified random-effects meta-analysis, OR (95% CI)   Meta-regression *P*-value for heterogeneity
  -------------------------------------- ------------------- ------------------------------------------------------ ---------------------------------------------
  **Study quality**                                                                                                 
  Lower (0--4)                           5                   4.98 \[−1.79, 11.76\]                                  0.1493
  High (5--7)                            24                  1.60 \[1.12, 2.08\]                                    \<0.0001
  **Combined medication or not**                                                                                    
  with CM                                14                  1.92 \[1.00, 2.84\]                                    \<0.0001
  without CM                             15                  1.04 \[0.40, 1.68\]                                    0.0014
  **Courses of medication**                                                                                         
  ≤3 months                              13                  1.57 \[1.13, 2.01\]                                    \<0.0001
  \>3 months                             15                  1.42 \[0.51, 2.33\]                                    0.0022
  Dosage of TWP                                                                                                     
  \<1 OR \>1.5 mg/kg/d                   14                  1.88 \[1.42, 2.35\]                                    \<0.0001
  \[1,1.5\] mg/kg/d                      15                  2.14 \[1.45, 2.83\]                                    \<0.0001
  **Pharmaceutical manufacturer**                                                                                   
  TZ                                     10                  1.43 \[0.47, 2.39\]                                    0.0036
  Others                                 9                   1.25 \[0.56, 1.93\]                                    0.0004
  **Organ-special AEs**                                                                                             
  Intestinal toxicity                    22                  0.87 \[0.64, 1.10\]                                    \<0.0001
  Reproductive toxicity                  15                  0.61 \[0.32, 1.02\]                                    0.0032
  Hepatotoxicity                         22                  0.87 \[0.47, 1.07\]                                    \<0.0001
  Nephrotoxicity                         6                   1.80 \[0.03, 3.57\]                                    0.0459
  Hematotoxicity                         15                  0.80 \[0.40, 1.20\]                                    \<0.0001
  Cutaneous toxicity                     8                   0.81 \[0.41, 1.20\]                                    \<0.0001
  Other damages                          11                  0.94 \[0.59, 1.28\]                                    \<0.0001

TWP, Tripterygium Wilfordii tgpolyglycoside; AEs, adverse events; CI, confidence interval; OR, odds ratio; SA: single-arm trials; CM, combined medication; TZ, Jiangsu Taizhou Pharmaceutical Co., Ltd.

Global Incidence of AEs Triggered by TWP {#s3_3}
----------------------------------------

Twenty-nine studies reported a specific number of AEs after using TWP (1563 patients with 578 events). The incidence of AEs in any grades and severe grade after TWP treatment was 30.75% \[95% CI (21.18--40.33), *I* ^2^ = 97%\] ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}) and 4.68% \[95% CI (0.00--12.72), *I* ^2^ = 53%), respectively ([**Supplementary Figure 2**](#SM1){ref-type="supplementary-material"}). Fifteen trials involved treatment with only TWP (1721 patients with 427 events), and the incidence of AEs in these trials was 40.14% \[95% CI (29.51--51.58), *I* ^2^ = 89%\]. Sixteen trials involved treatment with TWP plus combined drugs (574 patients with 147 events), and the incidence was 22.69% \[95% CI (15.04--32.75), *I* ^2^ = 77%) ([**Supplementary Figure 3**](#SM1){ref-type="supplementary-material"}).

In 36 trials, the TWP-induced AEs usually disappeared after discontinuing the medicine. Only one (with one patient) trial ([@B21]) showed that the AEs improved at the end of the treatment and disappeared in 3 weeks after withdrawal. However, there was no improvement in nephrotoxicity after 3 months of drug withdrawal in one trial (with one patient) ([@B42]).

In 32 trials, medical countermeasures were provided to alleviate the AEs, and continuous TWP treatment was discontinued in 15 clinical trials ([@B1]; [@B60]; [@B62]; [@B21]; [@B7]; [@B64]; [@B23]; [@B69]; [@B20]; [@B8]; [@B39]; [@B59]; [@B9]; [@B32]; [@B68]). In 7 of these 15 trials (with 40 patients), ([@B1]; [@B62]; [@B21]; [@B46]; [@B69]; [@B59]; [@B68]) the AEs disappeared after discontinuing TWP treatment, although they did not specifically discuss the conditions of the patients after drug withdrawal; only one trial ([@B42]) showed no improvement after 3 months of drug discontinuation. Treatment plan was not discontinued or changed in 6 of 46 studies (with 54 patients) as the AEs were mild and well controlled (28, 32, 47, 55, 56, 57. Furthermore, symptomatic treatment was provided in 6 of 46 trials, ([@B51]; [@B61]; [@B33]; [@B34]; [@B39]; [@B63]) reduced dosage was provided in 3 trials, ([@B13]; [@B11]; [@B58]) and 1 ([@B60]) trial involved change in the time of medicine administration after meals.

Course of Medication and Combined Medication {#s3_4}
--------------------------------------------

In 46 studies, 39.1% (18/46) of the diagnoses were related to urinary system diseases, 23.9% (11/46) to RA, 10.9% (5/46) to digestive system diseases, and 8.7% (4/46) to skin diseases (including 2 cases of psoriasis, 1 case of chronic urticaria, and 1 case of gangrenous pyoderma). There were two cases of Graves' eye disease, one case of uterine fibroids, one case of endometriosis, one case of oral lichen planus, one case of ankylosing spondylitis, one case of lupus erythematosus, and one case of periostitis. The details are shown in [**Figure 2**](#f2){ref-type="fig"}.

The incidence of AEs of all grades in patients without any combined medication was 40.16% \[95% CI (23.51--56.80), *I* ^2^ = 98%\], whereas that with combined medication was 22.69% \[95% CI (15.04--32.75), *I* ^2^ = 77%\]. The incidence of AEs was 33.86% \[95% CI (21.39--49.06), *I* ^2^ = 76%\] in patients (with 104 patients) treated with a combination of TWP and methotrexate (MTX), 21.81% \[95% CI (8.18--46.62), *I* ^2^ = 28%\] in patients (with 8 patients) treated with a combination of glucocorticoid and TWP, 30.48% \[95% CI (18.07--46.58), *I* ^2^ = 46%\] in patients (with 23 patients) treated with a combination of TWP and non-steroidal anti-inflammatory drugs (NSAIDs), 24.38% \[95% CI (5.67--63.37), *I* ^2^ = 50%\] in patients (with 26 patients) treated with a combination of TWP and antibiotic, 7.78% \[95% CI (1.00--41.36), *I* ^2^ = 83%\] in patients (with 9 patients) treated with combination of TWP and CHM, and 13.10% \[95% CI (4.73--31.40), *I* ^2^ = 63%, with 15 patients\] in patients treated with a combination of TWP and symptomatic medication. The detailed information on combined medication is shown in [**Table 3**](#T3){ref-type="table"} and [**Supplementary Figure 4**](#SM1){ref-type="supplementary-material"}.

###### 

Effect of estimates of AEs in the 46 studies included in this meta-analysis.

  Trials                                                        Any-grade AEs                                                
  ------------------------------------------------------------- ------------------------ ----- -------------------------- -- --
  **3.1 AEs with TWP combined with multiple drug treatments**                                                                
  **3.1.1 Combined with methotrexate**                                                                                       
  [@B51]                                                        8                        35    22.86 \[10.42, 40.14\]        
  [@B14]                                                        0                        12    0.00 \[0.00, 26.47\]          
  [@B32]                                                        34                       166   49.28 \[37.02, 61.59\]        
  [@B15]                                                        25                       69    25.77 \[17.43, 35.65\]        
  [@B19]                                                        0                        97    0.00 \[0.00, 97.5\]           
  [@B65]                                                        35                       1     50.73 \[38.41, 62.98\]        
  Meta-analysis                                                 33.86 \[21.39, 49.06\]   76%   \<0.01                        
  **3.1.2 Combined with glucocticoid**                                                                                       
  [@B21]                                                        1                        2     50.00 \[1.26, 98.74\]         
  [@B46]                                                        1                        15    6.67 \[0.17, 31.95\]          
  [@B29]                                                        6                        23    26.09 \[10.23, 48.41\]        
  Meta-analysis                                                 21.81 \[8.18, 46.62\]    28%   0.25                          
  **3.1.3 Combined with NSAIDs**                                                                                             
  [@B51]                                                        8                        35    22.86 \[10.42, 40.14\]        
  Yu-wen et al. (2005)                                          15                       40    37.50 \[22.73, 54.20\]        
  Meta-analysis                                                 30.48 \[18.07, 46.58\]   46%   0.17                          
  **3.1.4 Combined with antibiotic**                                                                                         
  [@B21]                                                        1                        1     1.00 \[2.50, 1.00\]           
  [@B14]                                                        0                        12    0.00 \[0.00, 26.47\]          
  [@B15]                                                        25                       97    25.77 \[17.43, 35.65\]        
  Meta-analysis                                                 24.38 \[5.57, 63.37\]    50%   \<0.01                        
  **3.1.5 Combined with Chinese medicine**                                                                                   
  [@B17]                                                        0                        31    0.00 \[0.00, 11.22\]          
  [@B69]                                                        7                        22    31.82 \[13.87, 54.87\]        
  [@B67]                                                        2                        52    3.85 \[0.47, 13.21\]          
  Meta-analysis                                                 7.78 \[1.00, 41.36\]     83%   \<0.01                        
  **3.1.6 Combined with symptomatic medication**                                                                             
  [@B21]                                                        2                        2     100.00 \[15.81, 100.00\]      
  [@B46]                                                        1                        15    6.67 \[0.17, 31.95\]          
  [@B14]                                                        0                        12    0.00 \[0.00, 26.47\]          
  [@B59]                                                        5                        45    11.11 \[3.71, 24.05\]         
  [@B38]                                                        6                        21    28.57 \[11.28,52.18\]         
  [@B48]                                                        1                        40    2.50 \[0.06, 13.16\]          
  Meta-analysis                                                 13.10 \[4.73, 31.40\]    63%   0.02                          
  **3.2 AEs with TWP combined with different dosages**                                                                       
  **3.2.1 \< 0.5 mg·kg/d**                                                                                                   
  [@B69] 0.3 mg·kg/d                                            7                        22    31.82 \[13.87, 54.87\]        
  **3.2.2 0.5 mg·kg/d**                                                                                                      
  [@B62] 0.5 mg·kg/d                                            32                       90    35.56 \[25.74, 46.35\]        
  [@B62] 0.6 mg·kg/d                                            38                       83    45.78 \[34.79, 57.08\]        
  [@B21] 0.5 mg·kg/d                                            1                        1     100 \[2.50, 100.00\]          
  [@B51] 0.5 mg·kg/d                                            8                        35    22.86 \[10.42, 40.14\]        
  [@B23] 0.5 mg·kg/d                                            29                       60    48.33 \[35.23, 61.61\]        
  [@B15] 0.5 mg·kg/d                                            25                       97    25.77 \[17.43, 35.65\]        
  Meta-analysis                                                 36.47 \[27.48, 46.51\]   67%   0.01                          
  **3.2.3 0.75 mg·kg/d**                                                                                                     
  [@B62] 0.7 mg·kg/d                                            13                       31    41.94 \[24.55, 60.92\]        
  [@B62] 0.8 mg·kg/d                                            29                       41    70.73 \[54.46, 83.87\]        
  [@B62] 0.9 mg·kg/d                                            39                       48    81.25 \[67.37, 91.05\]        
  [@B29] \[0.5,1\] mg·kg/d                                      6                        23    26.09 \[10.23, 48.41\]        
  [@B19] \[0.5,1\] mg·kg/d                                      0                        1     0.00 \[0.00, 97.50\]          
  Meta-analysis                                                 54.34 \[30.46, 76.37\]   84%   \<0.01                        
  **3.2.4 1 mg·kg/d**                                                                                                        
  [@B62] 1 mg·kg/d                                              18                       27    66.67 \[46.04, 83.48\]        
  [@B21] 1 mg·kg/d                                              1                        1     100.00 \[2.50, 100.00\]       
  [@B17] 1 mg·kg/d                                              0                        31    0.00 \[0.00, 11.22\]          
  Yu-wen et al. (2005) 1 mg·kg/d                                15                       40    37.50 \[22.73, 54.20\]        
  [@B14] 1 mg·kg/d                                              0                        12    0.00 \[0.00, 26.47\]          
  [@B36] 1 mg·kg/d                                              8                        21    38.10 \[18.11, 61.57\]        
  [@B32] 1 mg·kg/d                                              66                       138   47.83 \[39.26, 56.49\]        
  [@B59] 1 mg·kg/d                                              5                        45    11.11 \[3.71, 24.05\]         
  [@B38] 1 mg·kg/d                                              6                        21    28.57 \[11.28, 52.18\]        
  [@B48] 1 mg·kg/d                                              1                        40    2.50 \[0.06, 13.16\]          
  [@B50] 1 mg·kg/d                                              25                       58    43.10 \[30.16, 56.77\]        
  [@B66] 1 mg·kg/d                                              68                       138   49.28 \[40.67, 57.92\]        
  Meta-analysis                                                 33.75 \[23.92, 45.22\]   78%   \<0.01                        
  **3.2.5 1.5 mg·kg/d**                                                                                                      
  [@B60] 1.5 mg·kg/d                                            3                        30    10.00 \[2.11, 26.53\]         
  [@B68] 1.5 mg·kg/d                                            22                       45    48.89 \[33.70, 64.23\]        
  [@B67] 1.5 mg·kg/d                                            2                        52    3.85 \[0.47, 13.21\]          
  Meta-analysis                                                 14.86 \[2.24, 57.10\]    78%   \<0.01                        
  **3.2.6 \> 1.5 mg·kg/d**                                                                                                   
  [@B7] 2 mg·kg/d                                               23                       65    35.39 \[23.92, 48.23\]        
  [@B41] \[1.5,2\] mg·kg/d                                      40                       139   28.78 \[21.42,37.06\]         
  Meta-analysis                                                 30.96 \[24.98, 37.65\]   0%    0.34                          
  **3.3 Course treatment of AEs with TWP**                                                                                   
  **3.3.1 1 month**                                                                                                          
  [@B17] 1 month                                                0                        31    10.00 \[2.11, 26.53\]         
  Yu-wen et al. (2005) 6 weeks                                  15                       40    38.10 \[18.11, 61.57\]        
  [@B14] 6 weeks                                                0                        12    28.78 \[21.42, 37.06\]        
  [@B59] 1 month                                                5                        45    48.89 \[33.70, 64.23\]        
  Meta-analysis                                                 31.22 \[18.61, 47.41\]   76%   \<0.01                        
  **3.3.2 2 months**                                                                                                         
  [@B23] 2 months                                               29                       60    48.33 \[35.23, 61.61\]        
  [@B50] 2 months                                               25                       58    43.10 \[30.16, 56.77\]        
  Meta-analysis                                                 45.78 \[37.00, 54.82\]   0     0.57                          
  **3.3.3 3 months**                                                                                                         
  [@B1] 3 months                                                4                        87    4.60 \[1.27, 11.36\]          
  [@B62] 3 months                                               41                       85    48.24 \[37.26, 59.34\]        
  [@B51] 3 months                                               8                        35    22.86 \[10.42, 40.14\]        
  [@B46] 3 months                                               1                        15    6.67 \[0.17, 31.95\]          
  [@B61] 3 months                                               27                       55    49.10 \[35.35, 62.93\]        
  [@B67] 3 months                                               2                        52    3.85 \[0.47, 13.21\]          
  Meta-analysis                                                 17.73 \[7.02, 38.10\]    90%   \<0.01                        
  **3.3.4 6 months**                                                                                                         
  [@B62] \>3 months                                             118                      236   50.00 \[43.44, 56.56\]        
  [@B7] \[3,6\]months                                           23                       65    35.39 \[23.92, 48.23\]        
  [@B8] 6 months                                                13                       34    38.24 \[22.17, 56.44\]        
  [@B32] 6 months                                               66                       138   47.83 \[39.26, 56.49\]        
  [@B15] 6 months                                               25                       97    25.77 \[17.43, 35.65\]        
  [@B19] 6 months                                               0                        1     0.00 \[0.00, 97.50\]          
  [@B38] 6 months                                               6                        21    28.57 \[11.28, 52.18\]        
  [@B48] 6 months                                               1                        40    2.50 \[0.06, 13.16\]          
  [@B66] 6 months                                               68                       138   49.28 \[40.67, 57.92\]        
  Meta-analysis                                                 37.79 \[29.63, 46.69\]   77%   \<0.01                        
  **3.3.5 9 months**                                                                                                         
  [@B27] 9 months                                               6                        23    26.09 \[10.23, 48.41\]        
  **3.3.6 12 months**                                                                                                        
  [@B60] 12 months                                              3                        30    10.00 \[2.11, 26.53\]         
  [@B36] 12 months                                              8                        21    38.10 \[18.11, 61.57\]        
  [@B41] 12 months                                              40                       139   28.78 \[21.42, 37.06\]        
  [@B68] 12 months                                              22                       45    48.89 \[33.70, 64.23\]        
  Meta-analysis                                                 31.22 \[18.61, 47.41\]   76%   \<0.01                        
  **3.4 Medication treatment of AEs with TWP**                                                                               
  **3.4.1 Meitong Pharmaceutical**                                                                                           
  [@B1]                                                         4                        87    4.60 \[1.27, 11.36\]          
  [@B16]                                                        12                       13    92.31 \[64.00, 99.81\]        
  [@B62]                                                        159                      320   49.69 \[44.08,55.30\]         
  [@B51]                                                        8                        35    22.86 \[10.42, 40.14\]        
  [@B17]                                                        0                        31    0.00 \[0.00,11.22\]           
  [@B7]                                                         23                       65    35.39 \[23.92, 48.23\]        
  [@B8]                                                         13                       34    38.24 \[22.17, 56.44\]        
  [@B41]                                                        40                       139   28.78 \[21.42, 37.06\]        
  [@B68]                                                        22                       45    48.89 \[33.70, 64.23\]        
  [@B49]                                                        1                        34    2.94 \[0.07, 15.33\]          
  [@B15]                                                        25                       97    25.77 \[17.43, 35.65\]        
  [@B67]                                                        2                        52    3.85 \[0.47, 13.21\]          
  [@B48]                                                        1                        40    2.50 \[0.06, 13.16\]          
  Meta-analysis                                                 23.09 \[14.74, 34.26\]   89%   \<0.01                        
  **3.4.2 Zhejiang Deend Pharmaceutical**                                                                                    
  [@B14]                                                        0                        12    0.00 \[0.00, 26.47\]          
  [@B32]                                                        66                       138   47.83 \[39.26, 56.49\]        
  [@B27]                                                        6                        23    26.09 \[10.23, 48.41\]        
  Meta-analysis                                                 29.99 \[11.89, 57.63\]   75%   0.02                          
  **3.4.3 Huangshi Feijun Pharmaceutical**                                                                                   
  [@B36]                                                        8                        21    38.10 \[18.11, 61.57\]        
  [@B59]                                                        5                        45    11.11 \[3.71, 24.05\]         
  Meta-analysis                                                 21.84 \[5.54, 57.12\]    83%   0.01                          
  **3.4.4 Others**                                                                                                           
  Yu-wen et al. (2005)                                          15                       40    37.50 \[22.73, 54.20\]        
  [@B23]                                                        29                       60    48.33 \[35.23, 61.61\]        
  [@B60]                                                        3                        30    10.00 \[2.11, 26.53\]         
  Meta-analysis                                                 31.55 \[15.04, 54.54\]   81%   \<0.01                        

AEs, adverse events; TWP, Tripterygium wilfordii tgpolyglycoside; NSAIDs, non-steroidal anti-inflammatory drugs.

Dosage-Dependent Analysis of AEs {#s3_5}
--------------------------------

Twenty-nine of the 46 trials showed the number and grade of AEs after treatment with specific doses of TWP. The incidence of all types of AEs was 36.47% \[95% CI (27.48--46.51), *I* ^2^ = 0%\] in patients treated with 0.5 mg/kg/d TWP (6/46 studies, with 133 patients), 54.34% \[95% CI (30.46--76.37), *I* ^2^ = 84%\] in patients treated with 0.75 mg/kg/d TWP (5/46 studies, with 87 patients), 33.75% \[95% CI (23.92--45.22), *I* ^2^ = 87%\] in patients treated with 1.0 mg/kg/d TWP (12/46 studies, with 213 patients), 14.86% \[95% CI (2.24--57.10), *I* ^2^ = 91%\] in patients treated with 1.5 mg/kg/d TWP (3/46 studies, with 27 patients), and 30.96% \[95% CI (24.98--37.65), *I* ^2^ = 0%\] in patients treated with more than 1.5 mg/kg/d TWP (2/46, with 63 patients). The details are shown in [**Table 3**](#T3){ref-type="table"} and [**Supplementary Figure 5**](#SM1){ref-type="supplementary-material"}.

Forty-three of the 46 studies showed the dose frequency in the meta-analysis. We selected 15 of those trials that involved therapeutic doses ranging from 1 to 1.5 mg/kg/d to avoid heterogeneity, and counted the frequency of medicine consumption. However, in most studies (13/15), patients consumed the medicine thrice a day; hence, we could not determine the correlation between medicine consumption frequency and AEs.

Medication and AEs {#s3_6}
------------------

Twenty-six of the 46 trials showed the specific number of patients and the treatment duration with TWP. The incidence of AEs of all grades was 11.56% \[95% CI (2.92--36.24), *I* ^2^ = 79%\] in patients (4/46 studies, with 20 patients) treated with TWP for 1 month, 45.78% \[95% CI (37.00--54.82), *I* ^2^ = 0%\] in patients (2/46 studies, with 54 patients) treated with TWP for 2 months, 17.73% \[95% CI (7.02--38.10), *I* ^2^ = 90%) in patients (6/46 studies, with 83 patients) treated with TWP for 3 months, 37.79% \[95% CI (29.63--46.69), *I* ^2^ = 77%\] in patients (9/46 studies, with 320 patients) treated with TWP for 6 months, and 31.22% \[95% CI (18.61--47.41), *I* ^2^ = 76%\] in patients (4/46 studies, with 73 patients) treated with TWP for 12 months. Specific data are shown in [**Table 3**](#T3){ref-type="table"} and [**Supplementary Figure 6**](#SM1){ref-type="supplementary-material"}.

Pharmaceutical Manufacturer {#s3_7}
---------------------------

Thirty-five of the 46 studies clearly mentioned the name of the pharmaceutical manufacturer with specific events. The incidence of AEs was 23.01% \[95% CI (14.74--34.26), *I* ^2^ = 89%\] in patients (13/46, with 310 patients) treated with TWP manufactured by Jiangsu Meitong Pharmaceutical Co., Ltd.; 29.99% \[95% CI (11.89--57.63), *I* ^2^ = 75%\] in patients (3/46, with 72 patients) treated with TWP manufactured by Zhejiang Deend Pharmaceutical Co., Ltd.; 21.84% \[95% CI (5.54--57.12), *I* ^2^ = 83%\] in patients (2/46, with 13 patients) treated with TWP manufactured by Huangshi Feiyun Pharmaceutical Co., Ltd.; and 31.55% \[95% CI (15.04--54.54), *I* ^2^ = 81%\] per the rate provided by other pharmaceutical companies. The statistical details are shown in [**Table 3**](#T3){ref-type="table"} and [**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}.

Organ-Specific AEs {#s3_8}
------------------

We analyzed the incidence of AEs associated with intestinal toxicity, reproductive toxicity, hepatotoxicity, nephrotoxicity, hematotoxicity, and cutaneous toxicity during drug use. The most common AE of all grades caused by TWP was intestinal toxicity, followed by reproductive toxicity. The detailed information regarding organ-specific AEs is shown in [**Figure 4**](#f4){ref-type="fig"} and [**Supplementary Figure 8**](#SM1){ref-type="supplementary-material"}.

![Mapping of seven organ-specific adverse events of study type between 1994 and 2018. RCT, randomized controlled trial; CCT, controlled clinical trial; SA, single-arm trial.](fphar-10-01250-g004){#f4}

Intestinal Toxicity {#s3_9}
-------------------

The most common digestive AE during treatment with TWP was gastrointestinal discomfort, with an incidence of 13.88% \[95% CI (9.12--20.56), *I* ^2^ = 85%). In addition, gastric hemorrhage was a serious symptom in the digestive system, although the probability of occurrence was low ([**Supplementary Figure 9**](#SM1){ref-type="supplementary-material"}).

Reproductive Toxicity {#s3_10}
---------------------

Amenorrhea was the most frequent AE in patients treated with TWP, and its incidence was 10.16% \[95% CI (5.54--18.16), *I* ^2^ = 78%). No serious AE occurred in the reproductive system ([**Supplementary Figure 10**](#SM1){ref-type="supplementary-material"}).

Hepatotoxicity {#s3_11}
--------------

The incidence of increased levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) was 6.83% \[95% CI (3.87--11.77), *I* ^2^ = 62%\] without any serious hepatotoxic AEs ([**Supplementary Figure 11**](#SM1){ref-type="supplementary-material"}).

Nephrotoxicity {#s3_12}
--------------

The most frequent urinary system AE was proteinuria, with an incidence of 13.57% \[95% CI (6.87--25.07), *I* ^2^ = 54%\]. The incidence of elevated serum creatinine (SCr) or blood urea nitrogen (BUN) levels ranged from 6% to 8% after TWP treatment ([**Supplementary Figure 12**](#SM1){ref-type="supplementary-material"}).

Hematotoxicity {#s3_13}
--------------

The most common hematotoxic AE arising during the use of TWP was leukopenia, which might develop into a life-threatening severe AE. Fortunately, it was usually not critical and could be corrected by timely medical intervention. The incidence of hematotoxicity was 5.66% \[95% CI (4.27--7.47), *I* ^2^ = 25%\], and that of leukopenia was 5.74% \[95% CI (3.94--8.31), *I* ^2^ = 38%) ([**Supplementary Figure 13**](#SM1){ref-type="supplementary-material"}).

Cutaneous Toxicity {#s3_14}
------------------

The incidence of all grades of skin system AEs was less than 5%. The general AEs of the skin included scall, ulcers, and herpes zoster, which were not of severe grade ([**Supplementary Figure 14**](#SM1){ref-type="supplementary-material"}).

Other Damages {#s3_15}
-------------

The incidences of other damages caused by TWP, such as palpitation, headache, elevated blood sugar, and hair loss, were all \<5%. The incidence of other damages was 4.43% \[95% CI (2.92--6.67), *I* ^2^ = 72%\] at a low rate of AEs ([**Supplementary Figure 15**](#SM1){ref-type="supplementary-material"}).

Quality Assessment, Heterogeneity, and Publication Bias {#s3_16}
-------------------------------------------------------

The Cochrane Collaboration's tool was used to evaluate the RCTs' methodological qualities in the meta-analysis, and the NOS was used for CCTs and single-arm trials. The overall risk of bias was assessed as low risk. Hence, the quality of the studies included was satisfactory ([**Supplementary Tables 1 and 2**](#SM1){ref-type="supplementary-material"}).

The meta-regression analysis revealed that high-quality studies, combined medications, medication course, drug dosage, pharmaceutical manufacturer, and organ-specific AEs (P \< 0.05) had a significant effect on heterogeneity in the meta-analysis ([**Table 2**](#T2){ref-type="table"}).

The funnel plot and Egger's test were used for detecting publication bias, which showed an asymmetric distribution of trials along the side of the funnel ([**Supplementary Figure 16**](#SM1){ref-type="supplementary-material"}). TWP was used in the different groups of the included studies. Owing to the different variable properties in each article, the results of the meta-analysis may have been affected by interference from unrelated variables. Egger's test showed that *P* = 0.02364 (\< 0.05) indicated the presence of publication bias ([**Supplementary Figure 17**](#SM1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The purpose of this study was to review the safety of TWP and provide a reference for TwHF preparations. It must be noted that the conclusions of this study can only serve as a reference for AEs caused by preparation types besides TWP, as the main toxicity component triptolide in TwHF is removed in TWP ([@B44]). In addition, owing to the different forms of articles included in this meta-analysis, the amount of information contained in each article differs. As much as possible, we performed subgroup analysis for studies with the same characteristics, which may have led to differences in total study counts and subgroup study counts. However, incorporating different types of articles is also one of the major strengths of this meta-analysis. A study (which included 428 trials) published in 2016 reported that the incidence of all grades of AEs caused by TwHF preparations was 26.7% \[95% CI (24.8--28.8)\]. The results of that systematic review were similar to our findings, but it included all types of TwHF preparations and 94% (402/428) of the included trials were from Chinese databases ([@B57]). The use of all types of TwHF preparations might increase statistical heterogeneity, and literatures of low quality might lead to low quality of methodology. In this analysis, we excluded other types of TwHF preparations, and the articles were all from English databases to ensure the quality of the outcomes.

We included 46 trials with 2437 patients in this study. The incidence of AEs of all grades in patients treated with TWP was 30.75% ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). In comparison, the incidence of severe-grade AEs was only 4.68% ([**Supplementary Figure 2**](#SM1){ref-type="supplementary-material"}). This indicated that the incidence of severe grade AEs caused by TWP was fairly low and that the drug was safe to use. We also observed that the incidence of AEs caused by treatments with TWP without any combination medication was higher than that of AEs caused by TWP treatment combined with other therapeutic methods ([**Supplementary Figure 3**](#SM1){ref-type="supplementary-material"}). This indicated that TWP had relatively high toxicity, and hence, AEs could be triggered without combining TWP with other drugs. Next, we conducted a subgroup analysis of the trials according to the combinations of different interventions with TWP and observed the highest incidence in the TWP plus MTX group, followed by the TWP plus NSAIDs and TWP plus antibiotics groups. The group with the lowest incidence was TWP plus Chinese medicine ([**Table 3**](#T3){ref-type="table"}). Interestingly, the incidence of AEs caused by TWP with all types of combined medications was lower than that caused by TWP without any combination. This indicated that combination with other drugs may weaken the toxicity caused by TWP and reduce the occurrence of AEs ([**Supplementary Figure 4**](#SM1){ref-type="supplementary-material"}). A previous study ([@B2]) performed a similar subgroup analysis between TwHF monotherapy and combination therapy. Many of the symptoms, including leukopenia, gastrointestinal reactions, irregular menstruation, and abnormal liver function, were observed in patients on TwHF without any combinations at a higher frequency than in patients on combined therapy. However, this previous study included 36 RCTs that were reported in 2015. With the emergence of more evidence, systematic reviews should be updated in a timely manner. In our meta-analysis, high-quality RCTs, CCTs, and single-arm trials were added, and a set of rigid inclusion and exclusion criteria was used. The results proved that AEs observed after treatment with combined medications were related to the original toxicity of the drugs.

Furthermore, we observed that almost all AEs occurred during the duration of the medication. Meanwhile, AEs could be alleviated by reducing the dosage of the drugs or by changing the medicine consumption habit, such as consuming the medicine after meals. The AE grade was reduced after 3 months of drug withdrawal. This showed that the incidence of AEs decreased in patients treated with TWP when the drug was completely metabolized because of the recovery of bodily functions. However, the results might be related to case loss. The recommended dosage of TWP was 1−1.5 mg/kg/d, and we observed that the incidence of AEs with this dosage was 29.01% \[95% CI (20.17--39.79), *I* ^2^ = 82%\] ([**Supplementary Figure 18**](#SM1){ref-type="supplementary-material"}), which was lower than that in any other dosage groups. This indicated that either higher or lower dosage may lead to more serious AEs. In addition, the official recommended usage time is 3 months. We also observed an increase in AE incidence after more than 3 months of use ([**Supplementary Figure 19**](#SM1){ref-type="supplementary-material"}). Thus, TwHF should be used in moderation and for a short term.

We intended to statistically determine the relationship of age and gender with TWP application, although it could not be completed due to the lack of information. A study ([@B25]) showed that AEs caused by TwHF were more frequent in females than in males. Furthermore, toxicokinetic data indicated that TWP has gender-related differences in drug accumulation and toxicities, and that females are more sensitive to TWP toxicity than males ([@B29]). These results suggest that women should consider a protective agent for target organs when using TwHF. Owing to the effects of TWP on female menstruation and male sperm production, the most vulnerable age is the child-bearing age.

Previous data show that TwHF has several effective constituents, such as triptolide, triptonide, celastrol, and wilforine, with the most important being triptolide ([@B5]). These constituents are both the active ingredients and the source of toxicity ([@B6]). The mechanism of TwHF-induced AEs is complicated, and AEs occur in multiple systems and targets. The effect of TwHF on different systems is shown in [**Figure 5**](#f5){ref-type="fig"}. In addition, the immunoregulatory effects of TwHF are mainly directed to immune cells, immune molecules, and cellular signaling. TwHF exerts multidimensional regulatory activities on T cells and dendritic cells *in vivo* ([@B52]) ([**Figure 6**](#f6){ref-type="fig"}).

![Effective constituents of TwHF (such as triptolide, triptonide, celastrol, and wilforine) are both the active ingredients and toxicity source. TwHF induces toxicity in various target organs. In the digestive system, TwHF causes gastric mucosa irritation and increases the infiltration of inflammatory cells in the gastrointestinal tract. TwHF also disrupts the signaling of sex hormones and myeloperoxidase in reproductive organs, causes oxidative stress, increases the ratio of Th17/Treg, and suppresses hepatic gluconeogenesis. In the kidneys, TwHF decreases the activities of renal SOD and GSH and increases the level of MDA and BUN, resulting in serious oxidative stress and structural damage. TwHF can affect mitochondrial function and reduce the number of platelets, WBC, and lymphocytes. TwHF, *Tripterygium wilfordii* Hook F; ROS, reactive oxygen species; Plt, blood platelet; WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SCr, serum creatinine; BUN, blood urea nitrogen; SOD, superoxide dismutase; GSH, glutathione; MDA, malondialdehyde; WBC, white blood cell.](fphar-10-01250-g005){#f5}

![TwHF inhibits the activity of immune cells and prevents T-cell proliferation with the reduction in proinflammatory cytokines and chemokines; TwHF alters intracellular GSH levels, resulting in the overproduction of ROS, leading to mitochondrial damage; TwHF increases the generation of anion superoxide (O^2-^), inhibits the activity of antioxidant enzymes such as SOD and catalase, and induces oxidative stress and dysfunction in organs. Meanwhile, oxidative stress is an important factor in the induction of apoptosis. TwHF treatment activated caspase-3, caspase-8, and caspase-9, and p53 and downregulated Bcl-2 levels in mitochondria-initiated apoptosis. TwHF can increase the expression of GRP78 to inhibit endoplasmic reticulum stress and induce protective autophagy; it also inhibits apoptosis by eliminating dysfunctional mitochondria. TwHF, *Tripterygium wilfordii* Hook F; GSH, glutathione; ROS, reactive oxygen species; SOD, superoxide dismutase.](fphar-10-01250-g006){#f6}

In addition, the quality of a CHM is closely related to the quality of its active ingredients, which is important for both quality evaluation and control. The standard for the extraction of TWP in the market often considers wilforine as the main evaluation index, which is proposed as a biologically active and toxic component of TwHF ([@B52]). However, TwHF preparations produced by different manufacturers vary in chemical composition, which is consistent with clinical observations ([@B47]). To overcome this problem, we analyzed the drug produced by different pharmaceutical manufacturers ([**Table 3**](#T3){ref-type="table"}, [**Supplementary Figure 7**](#SM1){ref-type="supplementary-material"}) and observed that the heterogeneity between groups was large. This might be due to the lack of information and the fact that all the pharmaceutical companies were from China.

TWP is used in the treatment of various diseases, although it induces a wide spectrum of AEs. In the included trials, the most common AE was intestinal toxicity ([**Supplementary Figure 9**](#SM1){ref-type="supplementary-material"}), followed by reproductive toxicity ([**Supplementary Figure 10**](#SM1){ref-type="supplementary-material"}). To summarize, the main AEs that appeared in the included trials were as follows: (i) gastrointestinal tract stimulation, (ii) damage to the reproductive system, (iii) liver or kidney damage, (iv) AEs of skin mucosa, (v) leukopenia, (vi) induced arrhythmia, and (vii) infection or acute poisoning.

In summary, the toxicity of TwHF depends on the dose and time of administration. Notably, both high/short-term doses and low/long-term doses cause AEs ([@B22]). As each individual reacts differently to TWP, which may affect the accuracy of the meta-analysis, we used meta-regression to analyze and divide the subgroups to identify the sources of heterogeneity in this meta-analysis. As TwHF preparations have a prominent anti-inflammatory effect and are clinically irreplaceable, ([@B54]) we suggest that the clinical dosage of TwHF should be strictly controlled and its usage should be stringently monitored. Furthermore, toxicological studies on TwHF should be conducted to ensure the safety of TwHF preparations.

Our study has some limitations. First, some of the included studies were not RCTs, which was the main source of publication bias. Second, some key information was missing from some of the included studies; for instance, the number of certain specific AEs was not mentioned, and most studies showed the total number of AEs. Furthermore, the clinical environment was highly variable, and hence, the use of the random-effects models was important for controlling variability. Therefore, control variables were used to ensure the quality of the meta-analysis in the subgroup analysis of the drug characteristics and system. Simultaneously, the sample size of different subgroups was small, and some subgroups could not achieve the test effect.

In conclusion, our meta-analysis provided a statistical outline of AEs in patients treated with TWP. The included evidence was entirely from English databases, and the pattern of AE occurrence was organ-specific and related to TwHF.

Glossary {#s5}
========

TWP, *Tripterygium wilfordii* tgpolyglycoside; TwHF, *Tripterygium wilfordii* Hook F; AE, adverse event; CHM, Chinese herbal medicine; RCT, randomized controlled trial; CCT, controlled clinical trial; EMBASE, Excerpta Medica Database; WOS, Web of Science; CTCAE 5.0, the Common Terminology Criteria for Adverse Events 5.0; NOS, Newcastle--Ottawa Scale; CI, confidence interval; SCr, serum creatinine; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; NSAID, non-steroidal anti-inflammatory drug; MTX, methotrexate; RA, rheumatoid arthritis; ER, endoplasmic reticulum; HPLC, high-performance liquid chromatography.
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